ACCESS Newswire

The newsfeed available here is provided by our content partner ACCESS Newswire. This is one of the most important and widest-reaching press services, providing news, press releases and multimedia content to the media, journalists and the public.

The NewsWire Hub ("X-Billboard") currently comprises five of the most important international news sources and is supplemented by a stock market information service. The individual newswire services complement each other and form a complementary information offering that covers more than three quarters of the official news sources on which editorial offices worldwide base their stock market reporting. Your advantage: You will find everything here in one overview. You can navigate to the individual sections using the control elements. In the terminal view, you can carry out individual searches at company level.
presented by
N
More Tools & Gadgets
F&G: 75
6.398,93 S&P · 17,93 Vola-Index · 117.969,61 BTC · 1,17419 EURUSD
System-State: Number of processed items 14.782 Notifications successully processed since Inception
EXCHANGE NEWSBOARD
                              
NEWSWIRE INFOBOARD
                              

ACCESS Newswire is an important news source for private investors, investors and traders that can be accessed via the X-Billboard. It is part of the Newswire Hub, which bundles important international news sources for stock market players in one central location. If you want to get a quick overview, you can easily scroll through the headlines. Those who want to take a closer look at the news can use the detailed views of the info cards to directly access the respective news item and other analysis tools.

NEWS
EXPLORER
US60770K1079
State: 27.07.2025 | 2AM
Do you already know our new terminal view? Click here.
FIGI: BBG003PHHZT1
MRNA
Moderna, Inc.
GICS: - · Sector: Healthcare · Sub-Sector: Biotechnology
NAME
Moderna, Inc.
ISIN
US60770K1079
TICKER
MRNA
MIC
XNAS
REUTERS
MRNA.OQ
BLOOMBERG
MRNA US
Fri, 25.07.2025       Moderna
US60770K1079

Moderna's updated COVID-19 mRNA vaccine will be available for the 2025-2026 vaccination season, pending a European Commission authorization decision CAMBRIDGE, MA / ACCESS Newswire / July 25, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopte...
Read More
Moderna
Technical Analysis Termsheet Terminal
Permalink
Mon, 30.06.2025       Moderna
US60770K1079

mRNA-1010 demonstrated superior relative vaccine efficacy that was 26.6% (95% CI; 16.7%, 35.4%) higher than a licensed standard-dose seasonal influenza vaccine in adults aged 50 years and older CAMBRIDGE, MA / ACCESS Newswire / June 30, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced positive results from a Phase 3 efficacy study (P304) evaluati...
Read More
Moderna
Technical Analysis Termsheet Terminal
Permalink
Thu, 12.06.2025       Moderna
US60770K1079

Expanded indication builds on existing U.S. FDA approval of mRESVIA for adults aged 60 and older CAMBRIDGE, MA / ACCESS Newswire / June 12, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has approved mRESVIA® (mRNA-1345), the Company's respiratory syncytial virus (RSV) vaccine, for the preve...
Read More
Moderna
Technical Analysis Termsheet Terminal
Permalink
Silent Ad
Wed, 11.06.2025       Moderna
US60770K1079

CAMBRIDGE, MA / ACCESS Newswire / June 11, 2025 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor event:Barclays Speaking the Science Call Series, on Monday, June 16th at 10:00am ETA live webcast of this presentation will be available under "Events and Presentations" in the Investors secti...
Read More
Moderna
Technical Analysis Termsheet Terminal
Permalink
Sat, 31.05.2025       Moderna
US60770K1079

mNEXSPIKE becomes Moderna's third FDA-approved product CAMBRIDGE, MA / ACCESS Newswire / May 31, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has approved mNEXSPIKE® (mRNA-1283), a new vaccine against COVID-19, for use in all adults 65 and older, as well as individuals aged 12-64 years wit...
Read More
Moderna
Technical Analysis Termsheet Terminal
Permalink
Wed, 28.05.2025       Moderna
US60770K1079

Phase 1/2 H5 avian flu vaccine study shows positive interim resultsCompany has been notified that HHS will terminate Moderna's award for late-stage development of pre-pandemic influenza vaccines CAMBRIDGE, MA / ACCESS Newswire / May 28, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced positive interim data from a Phase 1/2 clinical study (NCT0597...
Read More
Moderna
Technical Analysis Termsheet Terminal
Permalink
Tue, 27.05.2025       Moderna
US60770K1079

CAMBRIDGE, MA / ACCESS Newswire / May 27, 2025 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor conferences:Jefferies Global Health Care Conference, on Thursday, June 5th at 10:30am ETGoldman Sachs 46th Annual Global Healthcare Conference, on Wednesday, June 11th at 8:40am ETA live webcast of each ...
Read More
Moderna
Technical Analysis Termsheet Terminal
Permalink
Fri, 23.05.2025       Moderna
US60770K1079

CAMBRIDGE, MA / ACCESS Newswire / May 23, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that it has submitted an application to the U.S. Food and Drug Administration (FDA) for review of its Spikevax 2025-2026 formula, targeting the SARS-CoV-2 variant LP.8.1. The submission is based on guidance from the U.S. FDA, which advised that COVID-19 vac...
Read More
Moderna
Technical Analysis Termsheet Terminal
Permalink
Wed, 21.05.2025       Moderna
US60770K1079

CAMBRIDGE, MA / ACCESSWIRE / May 21, 2025 / Moderna, Inc. (Nasdaq:MRNA), today announced that in consultation with the U.S. Food and Drug Administration (FDA), the Company has voluntarily withdrawn the pending Biologics License Application (BLA) for mRNA-1083, its flu/COVID combination vaccine candidate for adults aged 50 years and older. The Compa...
Read More
Moderna
Technical Analysis Termsheet Terminal
Permalink
Thu, 08.05.2025       Moderna
US60770K1079

CAMBRIDGE, MA / ACCESS Newswire / May 8, 2025 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor conference:Bernstein's 41st Annual Strategic Decisions Conference (SDC), on Thursday, May 29th at 10:00am ETA live webcast of each of these presentations will be available under "Events and Presentat...
Read More
Moderna
Technical Analysis Termsheet Terminal
Permalink
Silent Ad
Thu, 01.05.2025       Moderna
US60770K1079

Reports first quarter revenues of $0.1 billion, GAAP net loss of $(1.0) billion and GAAP EPS of $(2.52)Reiterates 2025 expected revenue range of $1.5 to $2.5 billion and 2025 year-end cash balance of approximately $6 billionAnnounces reduction of $1.4 to $1.7 billion in estimated GAAP operating costs by 2027Advancing up to 10 products toward approv...
Read More
Moderna
Technical Analysis Termsheet Terminal
Permalink
Thu, 10.04.2025       Moderna
US60770K1079

CAMBRIDGE, MA / ACCESS Newswire / April 10, 2025 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, May 1, 2025 to report its first quarter 2025 financial results, and provide a corporate update.A live webcast of the call will be available under "Events and Presentat...
Read More
Moderna
Technical Analysis Termsheet Terminal
Permalink
Mon, 07.04.2025       Moderna
US60770K1079

CAMBRIDGE, MA / ACCESS Newswire / 7. April 2025 / Moderna, Inc. (NASDAQ: MRNA) hat heute bekannt gegeben, dass das Unternehmen beim Weltkongress der European Society of Clinical Microbiology and Infectious Diseases (ESCMID), der von 11. bis 15. April 2025 in Wien (Österreich) stattfindet, eine Forschungsarbeit präsentieren wird, die sich ...
Read More
Moderna
Technical Analysis Termsheet Terminal
Permalink
Mon, 31.03.2025       Moderna
US60770K1079

CAMBRIDGE, MA / ACCESS Newswire / March 31, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Australian Therapeutic Goods Administration (TGA) has granted approval for mRESVIA® (mRNA-1345), an mRNA respiratory syncytial virus (RSV) vaccine, to prevent lower respiratory tract disease caused by RSV infection in adults aged 60 years an...
Read More
Moderna
Technical Analysis Termsheet Terminal
Permalink
Fri, 28.02.2025       Moderna
US60770K1079

mRESVIA® is Moderna's second approved product in the UK CAMBRIDGE, MA / ACCESS Newswire / February 28, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK has granted marketing authorization for mRESVIA (mRNA-1345), indicated for active immunization for the prevention...
Read More
Moderna
Technical Analysis Termsheet Terminal
Permalink
Tue, 25.02.2025       Moderna
US60770K1079

CAMBRIDGE, MA / ACCESS Newswire / February 25, 2025 / Moderna, Inc. (Nasdaq: MRNA), today announced its participation in the following upcoming investor conferences:TD Cowen 45th Annual Health Care Conference, on Wednesday, March 5th at 9:10am ETBarclays 27th Annual Global Healthcare Conference, on Tuesday, March 11th at 1:30pm ETA live webcast of ...
Read More
Moderna
Technical Analysis Termsheet Terminal
Permalink
Fri, 14.02.2025       Moderna
US60770K1079

Reports fourth quarter revenues of $1.0 billion, GAAP net loss of $(1.1) billion and GAAP EPS of $(2.91); loss includes approximately $0.2 billion of non-cash charges related to manufacturing resizingReports full-year revenues of $3.2 billion, GAAP net loss of $(3.6) billion and GAAP diluted EPS of $(9.28)Expects 2025 revenue range of $1.5 to 2.5 b...
Read More
Moderna
Technical Analysis Termsheet Terminal
Permalink
Wed, 29.01.2025       Moderna
US60770K1079

CAMBRIDGE, MA / ACCESS Newswire / January 29, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Friday, February 14, 2025 to report its fourth quarter and full year 2024 financial results, and provide a corporate update.A live webcast of the call will be available under "...
Read More
Moderna
Technical Analysis Termsheet Terminal
Permalink
Fri, 24.01.2025       Moderna
US60770K1079

/ Moderna, Inc. (NASDAQ: MRNA) hat heute bekannt gegeben, dass das Unternehmen im Rahmen einer Ausschreibung den Zuschlag für die Belieferung der Europäischen Union (EU) sowie Norwegen und Nord-Mazedonien mit seinem COVID-19-mRNA-Impfstoff erhalten hat. Die daraus resultierende Vereinbarung, an der 17 Länder teilnehmen, sieht eine Be...
Read More
Moderna
Technical Analysis Termsheet Terminal
Permalink
Fri, 17.01.2025       Moderna
US60770K1079

CAMBRIDGE, MA / ACCESS Newswire / January 17, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced ongoing support from the U.S. Department of Health and Human Services (HHS) to accelerate the development of mRNA-based pandemic influenza vaccines. The award was made through the Rapid Response Partnership Vehicle (RRPV) Consortium with funding from th...
Read More
Moderna
Technical Analysis Termsheet Terminal
Permalink
Silent Ad
Battery X Metals
Battery X Metals Reports Estimated 225 km Increase in Effective Driving Range Following Second Successful Rebalancing and First Successful Targeted Cell Replacement, Restoring Light-Duty Electric Vehicle to 265 km and Diagnosing Defective Cell That Had Se
© ACCESSWIRE
Cypher Metaverse
Cypher Metaverse Inc. Announces Closing of Financing
© ACCESSWIRE
Carbeeza
Carbeeza Inc. Announces CEO Appointment
© ACCESSWIRE
BioNxt
BioNxt Solutions Announces Closing of First Tranche of Convertible Debenture Unit Private Placement
© ACCESSWIRE
WiSA Technologies
New to The Street Show #680 to Air Saturday, July 26 at 6:30 PM EST on Bloomberg TV
© ACCESSWIRE
Reeltime Rentals
ReelTime's RLTR Outperforms All Major AI Stocks for Second Week in a Row - Two-Week Surge Hits 73% as RI Gains Traction with Samsung Launch, National Media Campaign, and Green Stock News Recognition
© ACCESSWIRE
Ares Dynamic Credit
Month-End Portfolio Data Now Available For Ares Dynamic Credit Allocation Fund, Inc.
© ACCESSWIRE
GameSquare
GameSquare Regains Compliance with Nasdaq's Minimum Bid Price Requirement
© ACCESSWIRE
Sadot Group
Sadot Group Inc. Announces Closing of Public Offering
© ACCESSWIRE
Silver Scott Mines
Revolutionary Seedless Wallet Launches with "Remember Me" Campaign, Offering 100,000 Silver Scott Token Grand Prize
© ACCESSWIRE
Medical Care Technologies
"The Grail Collection" Could Be a Game-Changer for MDCE (OTC:MDCE) - Jordan, Curry, and NBA Royalty Up for Bid
© ACCESSWIRE
Lantern Pharma
Lantern Pharma Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
© ACCESSWIRE
Moderna
EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's COVID-19 mRNA Vaccine Targeting the SARS-CoV-2 Variant LP.8.1
© ACCESSWIRE
SMC Entertainment
SMC Announces FINRA's Approval to Change Corporate Name and Stock Trading Symbol
© ACCESSWIRE
Solera National Bancorp
Solera National Bancorp Announces Second Quarter 2025 Financial Results
© ACCESSWIRE
Netlist
Netlist Schedules Second Quarter 2025 Financial Results and Conference Call
© ACCESSWIRE
Wellgistics Health
Wellgistics Health Converts $8.1M Debt to Equity
© ACCESSWIRE
SMX
The GENIUS Act Just Launched a New Economy; SMX (Security Matters) Was Already There
© ACCESSWIRE
C2 Blockchain
C2 Blockchain Inc. Acquires Additional 61.5 Million DOG Coins, Bringing Total Treasury to Over 133 Million
© ACCESSWIRE
Valeura Energy Inc.
Valeura Energy Inc. Announces Strategic Farm-in Agreement with PTTEP
© ACCESSWIRE
Barton Gold Holdings
Wudinna Gold Project Rights Acquisition Completed
© ACCESSWIRE
Flushing Financial
Flushing Financial Corporation Reports GAAP EPS Increase of 128% and Core EPS of 78% Year-Over-Year for the Second Quarter of 2025
© ACCESSWIRE
Pinetree Capital
Pinetree Capital Ltd Announces Unaudited Financial Results For The Period Ended June 30, 2025
© ACCESSWIRE
Rhinebeck Bancorp
Rhinebeck Bancorp, Inc. Reports Results for the Quarter Ended June 30, 2025
© ACCESSWIRE
Isabella Bank
Isabella Bank Corporation Reports Second Quarter 2025 Results
© ACCESSWIRE

The information provided here is not subject to any editorial processing. It is prepared fully automatically and enriched with additional information and further research options. The aim of the content is to provide information seekers with the relevant information quickly and easily. A link back to the information provider and owner ensures that the data prepared here can be compared with the source information if required. The newsboard does not show information in real time. Please contact the exchange operator for this information if required. There is no claim to completeness. High availability cannot be guaranteed. If you notice any errors in the functionality, please let us know using the "Report a Bug" form below.

RAW DATA PROCESSING means that raw data is processed without changing the content. The data is supplemented to improve the interpretation of the information in terms of usability.

Note: The newswire crosslink panel in the upper area allows you to quickly and conveniently access additional sources of information. In the terminal view, the news is filtered at company level and enables targeted research.

On behalf of the international investor community, we would like to thank AccessWire for providing the news and data feeds

 

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S